Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239184 | Bioinformation Therapy for Pancreatic Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03815461 | Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00438256 | Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01632306 | A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer | completed | Phase 1 / Phase 2 | 28 | Halozyme TherapeuticsINDUSTRY | 2 | Nov 30, 2018 | clinicaltrials |
| NCT03627390 | BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer | completed | Phase 2 | 16 | Meabco A/SINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00068432 | Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00460174 | Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01032057 | Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery(SCALOP) | completed | Phase 2 | 114 | Lisette NixonOTHER | 1 | Oct 26, 2018 | clinicaltrials |
| NCT00003677 | Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00276744 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | terminated | Phase 2 | 249 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00868114 | Direct Tumor Injection KLH-Pulsed Dendritic Cells in Unresectable Pancreatic Cancer | terminated | Phase 2 | 24 | Leo W. Jenkins Cancer CenterOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT00557492 | Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer | completed | Phase 2 | 59 | Amer ZureikatOTHER | 1 | Sep 25, 2018 | clinicaltrials |
| NCT03662035 | Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer(ASPC) | unknown | Phase 2 | 30 | Changzhou No.2 People's HospitalOTHER | 0 | Sep 19, 2018 | clinicaltrials |
| NCT02399137 | A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer(CARRIE) | completed | Phase 2 | 88 | Merrimack PharmaceuticalsINDUSTRY | 6 | Sep 18, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00078975 | 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer | completed | Phase 2 | 26 | University Health Network, TorontoOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT02967770 | Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer(PanCAN) | withdrawn | Phase 2 | 0 | Georgetown UniversityOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT03662412 | Study of Sirolimus in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00109941 | Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery(OGF) | completed | Phase 2 | 25 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01621243 | M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 128 | Momenta Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 29, 2018 | clinicaltrials |
| NCT03636308 | Nab-paclitaxel Plus S-1(AS) Versus Nab-paclitaxel Plus Gemcitabine(AG) in Patients With Advanced Pancreatic Cancer(ASAGPAC) | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01534637 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 22 | Wake Forest University Health SciencesOTHER | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02558894 | Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | completed | Phase 2 | 65 | AstraZenecaINDUSTRY | 6 | Aug 2, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT02241551 | Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 2 | Nathan Bahary, MDOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT00408564 | Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 39 | Medical University of South CarolinaOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT01921751 | High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 20 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 13, 2018 | clinicaltrials |
| NCT02345460 | Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study | terminated | Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00386399 | Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT02767752 | Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer(CHIPAC) | terminated | Phase 2 | 21 | Herlev HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT02331251 | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | terminated | Phase 1 / Phase 2 | 81 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT03498326 | Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer(GCRP) | recruiting | Phase 2 | 480 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01389440 | Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer(GEMCAD1003) | completed | Phase 2 | 24 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | May 18, 2018 | clinicaltrials |
| NCT01373164 | A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 170 | Eli Lilly and CompanyINDUSTRY | 6 | May 16, 2018 | clinicaltrials |
| NCT00889187 | Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01417000 | Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | completed | Phase 2 | 93 | Aduro Biotech, Inc.INDUSTRY | 1 | May 8, 2018 | clinicaltrials |
| NCT01458717 | Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer | completed | Phase 2 / Phase 3 | 58 | Seoul National University HospitalOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT03502343 | Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer | unknown | Phase 2 | 52 | Yonsei UniversityOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01888978 | Molecularly Tailored Therapy for Pancreas Cancer | completed | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT01280058 | Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01359007 | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer | terminated | Phase 2 | 5 | University of OklahomaOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01423604 | Study of Ruxolitinib in Pancreatic Cancer Patients(RECAP) | completed | Phase 2 | 136 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jan 25, 2019source: clinicaltrials